Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.
Boston, MA
- Tweets 2,190
- Following 302
- Followers 4,513
- Likes 108
Pinned Tweet
TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
timi.org/40th-anniversary-ti…
1
12
63
7,401
TIMI Study Group retweeted
The latest trials are reshaping cardiovascular disease prevention.
Join experts for a rapid review of the data behind GLP-1 RAs, PCSK9 inhibitors, obicetrapib & inflammation reduction — & what these emerging therapies could mean for clinical practice.
ow.ly/gZU450ZGbn5
1
1
11
3,417
Coverage in @MassGeneralNews of @rgiugliano's #ESCCongress presentation on mortality in VESALIUS-CV (TIMI 66) @EBohula
news.massgeneralbrigham.org/…
1
2
275
In DAPA ACT HF-TIMI 68, baseline NP levels were min assoc w/congestion markers but strongly assoc w/early risk of clinical outcomes. Relative tx effect of #dapagliflozin vs placebo on CV death or worsening HF over 2 mos consistent across NP tertiles. @DDBergMD #ESCCongress
6
14
641
Evolocumab assoc w/↓ rates of all-cause mortality (20%↓)/CV death (21%↓)/non-CV death (15%↓). Findings favored evo in subgroups & for specific causes of CV death. ↓ in non-CV deaths explained by ↓rates of non-fatal MI, stroke & IDR with evo @rgiugliano @ebohula #ESCCongress
8
9
4,999
In DAPA ACT HF-TIMI 68, in-hospital initiation of #dapagliflozin led to early and sustained improvements in multiple measures of congestion @andmsmall @DDBergMD #ESCCongress
8
13
1,773
Exploratory proteomic profiling analysis from TRANSLATE-TIMI-70 identifies novel biomarkers that change after inhibition of ANGPTL3 with #vupanorsen @rishibansalmd @BrianBergmark #ESCCongress
2
2
390
Dr. Eileen O'Meara will present her work on natriuretic peptides in acute decompensated heart failure in the DAPA ACT HF-TIMI 68 trial, tomorrow at 12:15pm in Station 6 (Research Gateway-Hall A1) @DDBergMD #ESCCongress
2
3
348
In 24 hours in Tripoli (Hall B1), Dr. @rgiugliano will present a prespecified analysis of the effects of #evoclocumab on fatal outcomes in pts w/o prior MI or stroke in #VESALIUS-CV (TIMI 66) @ebohula #ESCCongress
1
322
See Dr. @andmsmall present his work on in-hospital initiation of #dapagliflozin on decongestion-related endpoints in acute HF, in a prespecified analysis of the DAPA ACT HF-TIMI 68, tomorrow at 5:15pm in Achgabat @DDBergMD #ESCCongress
1
3
304
Results from a protein profiling analysis of the TRANSLATE-TIMI-70 trial investigating the effect of the ANGPTL3 synthesis inhibiting drug, vupanorsen, will be presented on tomorrow at Station 7 (Research Gateway-Hall A1) at 4:15pm. @rishibansalmd @BrianBergmark #ESCCongress
3
323
In patients with atherosclerosis and/or high-risk diabetes, but without a prior myocardial infarction or stroke, #evolocumab significantly reduces not only first but also subsequent cardiovascular events during a median follow-up of 4.6 years. #VESALIUS @ebohula #ESCCongress
3
748
In AZALEA-TIMI 71, compared with rivaroxaban, #abelacimab substantially reduced the totality of bleeding across a wide variety of bleeding endpoints. @SidPatelMD #ESCCongress
7
14
1,265
In pts w/severe hypertriglyceridemia (TG >500 mg/dL), longer term use of #olezarsen → 2 yrs: Was generally well tolerated; Sustained TG ↓ of 68-79%; Resulted in 90% pts achieving TG levels <500 mg/dL; achieved ↓ in the risk of acute pancreatitis. @rgiugiano #ESCCongress
6
8
498
Dr. Jose Nicolau presents a total events analysis of #VESALIUS-CV (TIMI 66), tomorrow at 2:30pm in Science Box 5 (Research Gateway-Hall A1) @ebohula #ESCCongress
2
306
Intensive LDL-C lowering to ~45mg/dL w/#evolocumab reduced first MIs by 36% among patients without prior CV events from VESALIUS-CV. MIs were reduced within the first six months. The findings support plaque stabilization as the principal biological mechanism @bohula #ESCCongress
2
33
128
8,348
See Dr. @SidPatelMD speak on the total bleeding events in AZALEA-TIMI 71, tomorrow at 10am in Science Box 2 (Research Gateway-Hall A1) #ESCCongress
1
4
297
Dr. Gaetano de Ferrari presents results on the occurrence of a first MIs among patients without prior CV events enrolled in the #VESALIUS-CV trial, Friday at 11:15 AM in Science Box 5, Research Gateway, Hall A1. @ebohula #ESCCongress
1
240
Tomorrow at 8:15am in Vienna (ICM), Dr. @rgiugliano shows the long-term efficacy and safety of #olezarsen in the TIMI CORE 72a + B Open Label Extension #ESCCongress
1
5
446
Drs. @marstonMD and @rgiugliano discuss ground-breaking results of intensive LDL-C lowering in patients without prior MI or stroke, including those with no known atherosclerosis
lipidjournal.com/article/S19…
3
505